medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 13, 2023
Abstract
Biological
evidence
suggests
ursodeoxycholic
acid
(UDCA)
-
a
common
treatment
of
cholestatic
liver
disease
may
prevent
severe
COVID-19
outcomes.
With
the
approval
NHS
England,
we
conducted
population-based
cohort
study
using
primary
care
records,
linked
to
death
registration
data
and
hospital
records
through
OpenSAFELY-TPP
platform.
We
estimated
hazard
hospitalisation
or
between
1
March
2020
31
December
2022,
comparing
UDCA
no
in
population
with
indication.
Of
11,320
eligible
individuals,
642
were
hospitalised
died
during
follow-up,
402
(63%)
events
among
users.
After
confounder
adjustment,
was
associated
21%
(95%
CI
7%-33%)
relative
reduction
death,
consistent
an
absolute
risk
1.3%
1.0%-1.6%).
Our
findings
support
calls
for
clinical
trials
investigating
as
preventative
measure
npj Biofilms and Microbiomes,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: Aug. 1, 2024
Abstract
The
clinical
course
of
COVID-19
is
variable
and
often
unpredictable.
To
test
the
hypothesis
that
disease
progression
inflammatory
responses
associate
with
alterations
in
microbiome
metabolome,
we
analyzed
metagenome,
cytokine,
transcriptome
profiles
repeated
samples
from
hospitalized
patients
uninfected
controls,
leveraged
information
post-hoc
confounder
analysis.
Severe
was
associated
a
depletion
beneficial
intestinal
microbes,
whereas
oropharyngeal
microbiota
disturbance
mainly
linked
to
antibiotic
use.
severity
also
enhanced
plasma
concentrations
kynurenine
reduced
levels
several
other
tryptophan
metabolites,
lysophosphatidylcholines,
secondary
bile
acids.
Moreover,
various
metabolites
were
Faecalibacterium
,
decrease
increase
production
cytokines.
Collectively,
our
study
identifies
correlated
metabolome
as
potential
contributor
dysregulation
severe
COVID-19.
Journal of Medical Virology,
Journal Year:
2024,
Volume and Issue:
96(1)
Published: Jan. 1, 2024
Recent
data
suggest
that
ursodeoxycholic
acid
(UDCA)
therapy
may
reduce
susceptibility
to
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
and
even
improve
clinical
outcomes
when
disease-2019
(COVID-19)
was
diagnosed.
However,
evidence
of
UDCA's
ability
prevent
forms
COVID-19
remains
limited
contradictory.
We
evaluated
the
association
between
UDCA
exposure
risk
hospitalization
for
in
a
large
multicenter
population
patients
with
chronic
liver
disease
(CLD)
followed
during
pandemic
period
before
vaccination.
An
exposed/unexposed
cohort
study
nested
case-control
were
performed.
The
primary
endpoint
COVID-19,
defined
as
SARS-CoV2
requiring
hospitalization.
secondary
COVID-19-associated
intensive
care
unit
(ICU)
admission
or
death.
Adjusted
odds
ratios
(aOR)
their
confidence
intervals
(CI)
determined
after
controlling
age,
gender,
comorbidities
at
severity
CLD,
prior
hospitalizations.
A
total
10
147
patients,
including
1322
exposed
8825
not
UDCA,
totaling
21
867
person-years
follow-up,
included
analysis,
while
88
hospitalized
840
matched
controls
eligible
analysis.
In
both
analyses,
associated
significant
reduction
aOR
(95%
interval)
values
0.48
(0.20-1.19)
0.93
(0.26-3.29),
respectively.
Furthermore,
there
no
ICU
this
reduced
COVID-19.
Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Objective
Although
the
management
of
coronavirus
disease
2019
(COVID-19)
has
improved,
chemoprevention
remains
a
challenge.
We
recently
identified
that
ursodeoxycholic
acid
(UDCA)
is
associated
with
subclinical
infection
severe
acute
respiratory
syndrome
coronavirus,
implying
reduction
in
severity
COVID-19.
analyzed
large
medical
database
to
assess
utility
UDCA
COVID-19
severity.
Methods
This
retrospective
observational
study
was
conducted
using
large-scale
healthcare
administrative
claims
database.
extracted
data
on
patients
who
were
diagnosed
either
chronic
hepatitis
B
or
C.
Among
them,
>50
years
age
before
December
2022
analyzed.
Patients
divided
into
two
groups:
those
without
prescription
UDCA.
The
primary
outcome
in-hospital
mortality
rate.
A
propensity
score-matching
analysis
performed
logistic
regression.
Results
total
6,413
(UDCA
group,
n
=579;
non-UDCA
=5,834)
median
73.0
(IQR,
64.0-81.0)
years,
and
57.8%
men.
group
had
significantly
more
complications
liver
cirrhosis,
hepatocellular
carcinoma,
type
2
diabetes,
hypertension.
higher
rate
than
even
after
score
matching
(7.4%
vs.
4.3%,
p
=0.03),
whereas
there
no
difference
risks
hospitalization,
oxygen
therapy,
ventilation.
Conclusions
observed
increase
among
users
could
have
been
due
unmeasured
confounding
factors,
did
not
reduce
viral
patients.
Frontiers in Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: Feb. 6, 2025
The
potential
effect
of
ursodeoxycholic
acid
(UDCA)
on
the
clinical
outcomes
SARS-CoV-2
in
patients
with
chronic
liver
diseases
has
been
a
subject
ongoing
debate
since
onset
pandemic
2019.
This
study
aims
to
investigate
UDCA
prognosis
infection
diseases.
A
total
926
who
contracted
their
first
during
December
2022
January
2023,
were
included
this
study.
Participants
divided
into
two
groups
based
use
UDCA:
cohort
(n
=
329)
and
non-UDCA
597).
After
performing
1:1
age-and
sex-matching,
analysis
proceeded
309
from
each
group
for
further
evaluation.
In
UDCA-treated
cohort,
incidence
asymptomatic
infections
was
significantly
higher,
30.1%
affected,
compared
6.47%
(p
<
0.0001).
Multivariable
identified
as
protective
factor
against
symptomatic
infections,
yielding
an
odds
ratio
(OR)
4.77
(95%
CI:
2.70-8.44,
p
0.001).
Furthermore,
age
over
50
found
be
risk
adjusted
OR
1.51
1.01-2.24,
0.05).
suggests
that
therapy
may
improve
are
infected
SARS-CoV-2,
highlighting
its
role
improving
within
vulnerable
population.
However,
research
is
required
validate
these
findings
elucidate
mechanisms
underlying
UDCA's
effect.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(5), P. 1939 - 1950
Published: Feb. 13, 2024
The
coronavirus
disease
2019
(COVID-19)
pandemic,
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
has
been
significantly
alleviated.
However,
long-term
health
effects
and
prevention
strategy
remain
unresolved.
Thus,
it
is
essential
to
explore
the
pathophysiological
mechanisms
intervention
for
SARS-CoV-2
infection.
Emerging
research
indicates
a
link
between
COVID-19
bile
acids,
traditionally
known
facilitating
dietary
fat
absorption.
acid
ursodeoxycholic
potentially
protects
against
infection
inhibiting
farnesoid
X
receptor,
nuclear
receptor.
activation
of
G-protein-coupled
another
membrane
receptor
also
found
regulate
expression
angiotensin-converting
enzyme
2,
through
which
virus
enters
human
cells.
Here,
we
review
latest
basic
clinical
evidence
linking
acids
SARS-CoV-2,
reveal
their
complicated
mechanisms.
Pharmacological Reviews,
Journal Year:
2024,
Volume and Issue:
76(6), P. 1221 - 1253
Published: July 8, 2024
Bile
acids
are
the
end
products
of
cholesterol
catabolism.
Hepatic
bile
acid
synthesis
accounts
for
a
major
fraction
daily
turnover
in
humans.
Biliary
secretion
generates
flow
and
facilitates
biliary
lipids,
endogenous
metabolites,
xenobiotics.
In
intestine,
facilitate
digestion
absorption
dietary
lipids
fat-soluble
vitamins.
Through
activation
nuclear
receptors
G
protein-coupled
interaction
with
gut
microbiome,
critically
regulate
host
metabolism
innate
adaptive
immunity
involved
pathogenesis
cholestasis,
metabolic
dysfunction-associated
steatotic
liver
disease,
alcohol-associated
type-2
diabetes,
inflammatory
bowel
diseases.
their
derivatives
have
been
developed
as
potential
therapeutic
agents
treating
chronic
diseases
gastrointestinal
disorders.
SIGNIFICANCE
STATEMENT:
solubilization
lipid
absorption,
immunity,
modulate
microbiome.
Targeting
signaling
holds
promise
Expert Review of Anti-infective Therapy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 12
Published: July 8, 2024
Background
The
potential
of
ursodeoxycholic
acid
(UDCA)
in
inhibiting
angiotensin-converting
enzyme
2
was
demonstrated.
However,
conflicting
evidence
emerged
regarding
the
association
between
UDCA
and
COVID-19
outcomes,
prompting
need
for
a
comprehensive
investigation.
JMIR Public Health and Surveillance,
Journal Year:
2024,
Volume and Issue:
10, P. e59274 - e59274
Published: Aug. 14, 2024
Background
Several
studies
have
investigated
the
relationship
between
ursodeoxycholic
acid
(UDCA)
and
COVID-19
infection.
However,
complex
conflicting
results
generated
confusion
in
application
of
these
results.
Objective
We
aimed
to
investigate
whether
association
UDCA
infection
can
also
be
demonstrated
through
analysis
a
large-scale
cohort.
Methods
This
retrospective
study
used
local
nationwide
cohorts,
namely,
Jeonbuk
National
University
Hospital
into
Observational
Medical
Outcomes
Partnership
common
data
model
cohort
(JBUH
CDM)
Korean
Health
Insurance
Service
claim–based
database
(NHIS).
intake
its
with
susceptibility
severity
using
validated
propensity
score
matching.
Results
Regarding
susceptibility,
adjusted
hazard
ratio
(aHR)
value
was
significantly
lowered
0.71
case
JBUH
CDM
(95%
CI
0.52-0.98)
0.93
0.90-0.96)
NHIS.
severity,
found
0.21
0.09-0.46)
CDM.
Furthermore,
aHR
0.77
NHIS
0.62-0.95).
Conclusions
Using
cohort,
we
confirmed
that
associated
reductions
severity.
These
trends
remained
consistent
regardless
dosage.
suggests
potential
as
preventive
therapeutic
agent
for
Virology Journal,
Journal Year:
2024,
Volume and Issue:
21(1)
Published: Aug. 27, 2024
Conflicting
evidence
exists
regarding
the
effects
of
ursodeoxycholic
acid
(UDCA)
on
coronavirus
disease
2019
(COVID-19).
This
study
investigates
association
between
UDCA
administration
and
COVID-19
infection
its
related
outcomes
in
individuals
with
chronic
liver
(CLD).
A
customized
research
database
(n
=
3,485,376)
was
created
by
integrating
data
from
National
Health
Insurance
Service
(NHIS)
Korea
Disease
Control
Prevention
Agency's
databases.
The
focused
patients
diagnosed
2021,
using
NHIS
365
days
before
diagnosis.
To
create
comparable
groups
without
COVID-19,
we
used
propensity
score
matching.
primary
endpoint
first
confirmed
positive
result
for
severe
acute
respiratory
syndrome
coronavirus-2.
In
addition,
identified
COVID-19-related
outcomes.
Subgroup
analysis
were
conducted
based
dose
exposure.
Data
74,074
CLD
analyzed.
participants'
average
age
57.5
years,
52.1%
(19,277)
those
each
group
male.
Those
prior
exposure
had
a
significantly
lower
risk
(adjusted
OR:
0.80,
95%
CI
[0.76–0.85])
compared
to
non-UDCA
group.
Additionally,
0.67,
[0.46–0.98]).
analyses
indicated
that
there
decrease
increasing
dose.
Our
large
observational
highlights
potential
use
readily
available
as
an
adjunctive
therapy
CLD.
